Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report

Liang,Yi‑Chen; Wu,Gang; Cheng,Jing; Yu,Dan‑Dan; Wu,Hong‑Ge

doi:10.3892/ol.2015.3463

September-2015 Volume 10 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 10 Issue 3

Full Size Image

Case Report Open Access

Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report

Authors:
- Yi‑Chen Liang
- Gang Wu
- Jing Cheng
- Dan‑Dan Yu
- Hong‑Ge Wu
View Affiliations / Copyright

Affiliations: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China

Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 1277-1280
|
Published online on: July 8, 2015

https://doi.org/10.3892/ol.2015.3463
Expand metrics +

Abstract

Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dermatological reactions are the most common adverse events associated with gefitinib treatment; other adverse effects, including diarrhea, nausea, stomatitis and an asymptomatic elevation of liver enzymes have also been reported. The present study describes a patient with intestinal obstruction who was successfully undergoing treatment with gefitinib for primary and metastatic neoplasms. Gefitinib‑induced intestinal obstruction has not been previously reported; therefore, careful monitoring of gastrointestinal symptoms should be conducted throughout the course of gefitinib-treated malignancies.

View Figures

View References

1	Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000.PubMed/NCBI
2	Ettinger DS: Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer. Oncologist. 11:358–373. 2006. View Article : Google Scholar : PubMed/NCBI
3	Haaland B, Tan PS, de Castro G Jr and Lopes G: Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 9:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
4	Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 24:25–35. 2006. View Article : Google Scholar : PubMed/NCBI
5	Hartmann JT and Kanz L: Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 144:1525–1526. 2008. View Article : Google Scholar : PubMed/NCBI
6	Hotta K, Kiura K, Takigawa N, et al: Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: The Okayama Lung Cancer Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar : PubMed/NCBI
7	Nakagawa M, Nishimura T, Teramukai S, et al: Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. BMC Res Notes. 2:1572009. View Article : Google Scholar : PubMed/NCBI
8	Passaro A, Di Maio M, Del Signore E, Gori B and de Marinis F: Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: A comparison analysis. Clin Lung Cancer. 15:307–312. 2014. View Article : Google Scholar : PubMed/NCBI
9	Madke B, Gole P, Kumar P and Khopkar U: Dermatological side effects of epidermal growth factor receptor inhibitors: ‘PRIDE’ complex. Indian J Dermatol. 59:271–274. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles